Latest Share Chat

REMOVE ADS

Glaxosmithkline Share News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes

Get Live Data

1,913.50 -24.50 (-1.26%)

Bid:

1,913.50

Ask:

1,914.00

Spread: 0.50 (0.026%)

Market Cap: £76.74b

Last checked at -

Intraday Glaxosmithkline Share Chart

REMOVE ADS

Glaxosmithkline News

LONDON BRIEFING: Shell launches new buyback; WPP cuts revenue outlook

(Alliance News) - Shell launches new USD3.5 billion buyback, WPP cuts its outlook while Permanent TSB puts itself up for sale.

LONDON MARKET CLOSE: Stocks mixed ahead of Fed call, Trump-Xi talks

(Alliance News) - Stock prices in London closed mostly higher on Wednesday, as the US Federal Reserve's interest rate decision comes closer.

LONDON MARKET MIDDAY: FTSE 100 hits new record amid strong results

(Alliance News) - Stock prices in London were higher at midday on Wednesday, as the FTSE 100 achieved a new record and outperformed European peers aft...

LONDON MARKET OPEN: FTSE 100 hits high as Next and GSK raise guidance

(Alliance News) - Stock prices in London opened higher on Wednesday and hit a new intra-day record after a swathe of well-received reports from Glenco...

GSK lifts sales and profit outlook as Specialty Medicines unit shines

(Alliance News) - GSK PLC on Wednesday raised guidance after a strong third quarter, which saw sales in all three divisions beat expectations.

LONDON BRIEFING: GSK ups 2025 outlook; Next sales beat guidance

(Alliance News) - GSK raises its outlook for revenue and profit, Next ups its guidance as third quarter sales beat expectations, while Primary Health ...

GSK posts better-than-expected Q3, upgrades guidance

(Sharecast News) - GSK raised its full-year guidance on Wednesday, after delivering stronger-than-expected third-quarter results, driven by robust gro...

GSK strikes license deal with Empirico; gets cancer drug designation

(Alliance News) - GSK on Tuesday said it will pay up to USD745 million, plus royalties, as part of a license deal with US biotechnology company Empiri...